What happened
SRX Global Inc. (NYSE American: SRXH) signed a stock purchase agreement on October 6, 2026, to buy CERo Therapeutics, Inc. The seller is CERo Therapeutics Holdings, Inc., and the target is its wholly owned operating subsidiary, CERo Therapeutics, Inc. SRX will issue Holdings shares of SRX common stock for $1 million, priced at the lower of the prior day's closing price or the 20-day VWAP.
SRX will also forgive the Consolidated Note. Its original principal amount was up to $11.67 million, and its outstanding principal balance was $8.25 million as of the report date. The forgiveness also covers accrued and unpaid interest, fees and expenses. SRX will assume liabilities of about $1.56 million. The agreement extends the note's maturity to five business days after closing or termination and gives Holdings a 30-day go-shop period.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| CERo Acquired Debt | $2.81 million | Stock Purchase Agreement | |
| Stock consideration | $1 million | SEC 8-K | |
| Consolidated Note original principal | up to $11.67 million | SEC 8-K | |
| Outstanding principal balance | $8.25 million | SEC 8-K | |
| Assumed liabilities | approximately $1.56 million | SEC 8-K |
Why it matters
OptimistFi's case is that SRXH is a high-risk turnaround that needs a new platform and cash runway before dilution or losses overwhelm common holders. This filing cuts both ways. OptimistFi's calculation puts the gap between the note's original principal amount and the reported outstanding balance at about $3.42 million before accrued interest, fees and expenses. That is debt relief, but it still leaves stock issuance and assumed liabilities in place.
The deal is partly stock-based and adds about $1.56 million of liabilities, so common holders still face dilution from the share issuance. The transaction is also conditional. The filing says SRX must complete the Series C, Series D and Series E preferred-stock purchases and the Series A waivers or conversions before closing. Holdings can seek a Superior Proposal during the go-shop, and the filing says there can be no assurance that the transaction will be completed.
Browse: stock research on every company OptimistFi covers
What's next
The next dated milestone is the end of the 30-day go-shop period. Closing is expected on the first business day after the stated conditions are satisfied or waived, unless the parties agree otherwise in writing. The filing also gives Holdings up to 45 additional days after the go-shop ends to negotiate a Superior Proposal. If Holdings accepts one, or if conditions are not met, the deal may not close.
A completed closing would support the view that SRX has locked in debt relief and a new acquisition. A failed process would leave the acquisition, the debt discharge and the liability assumption unresolved.
More from OptimistFi
- SRXH stock: the SRX Global thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Current report announcing the Stock Purchase Agreement and related closing conditions.
- Exhibit 10.1 Stock Purchase Agreement — Purchase agreement setting out the acquisition terms, debt treatment and go-shop provisions.
Read the full OptimistFi thesis on SRX Global Inc.: https://optimistfi.com/stocks/SRXH
See what would break the SRX Global Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full SRX Global Inc. investment case, its status and the next test to watch live on the SRX Global Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
